Literature DB >> 20042495

Epstein-Barr virus-encoded Bcl-2 homologue functions as a survival factor in Wp-restricted Burkitt lymphoma cell line P3HR-1.

Ami Watanabe1, Seiji Maruo, Taku Ito, Miho Ito, Koichi Ricardo Katsumura, Kenzo Takada.   

Abstract

Burkitt lymphoma (BL) is etiologically associated with Epstein-Barr virus (EBV). EBV-positive BL tumors display two latent forms of infection. One is referred to as latency I infection, in which EBV expresses the virus genome maintenance protein EBNA1 as the only viral protein. The other is referred to as Wp-restricted latency and was recently identified in a subset of BL tumors. In these tumors, EBV expresses EBNA1, EBNA3A, EBNA3B, EBNA3C, a truncated form of EBNA-LP, and the viral Bcl-2 homologue BHRF1, all of which are driven by the BamHI W promoter (Wp). To investigate the role of EBV in Wp-restricted BL, we conditionally expressed a dominant-negative EBNA1 (dnEBNA1) mutant which interrupts the virus genome maintenance function of EBNA1 in the P3HR-1 BL cell line. Induction of dnEBNA1 expression caused loss of the EBV genome and resulted in apoptosis of P3HR-1 cells in the absence of exogenous apoptosis inducers, indicating that P3HR-1 cells cannot survive without EBV. Stable transfection of the BHRF1 gene into P3HR-1 cells rescued the cells from the apoptosis induced by dnEBNA1 expression, whereas stable transfection of truncated EBNA-LP, EBNA3A, or EBNA3C did not. Moreover, knockdown of BHRF1 expression in P3HR-1 cells resulted in increased cell death. These results indicate that EBV is essential for the survival of P3HR-1 cells and that BHRF1 functions as a survival factor. Our finding implies a critical contribution of BHRF1 to the pathogenesis of Wp-restricted BLs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20042495      PMCID: PMC2826050          DOI: 10.1128/JVI.01616-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  Development of a monoclonal antibody against Epstein-Barr virus nuclear antigen leader protein (EBNA-LP) that can detect EBNA-LP expressed in P3HR1 cells.

Authors:  Fumio Shaku; Go Matsuda; Rie Furuya; Chinatsu Kamagata; Mie Igarashi; Michiko Tanaka; Mikiko Kanamori; Yukihiro Nishiyama; Naoki Yamamoto; Yasushi Kawaguchi
Journal:  Microbiol Immunol       Date:  2005       Impact factor: 1.955

2.  Epstein-barr virus-induced resistance to drugs that activate the mitotic spindle assembly checkpoint in Burkitt's lymphoma cells.

Authors:  Maria Leao; Emma Anderton; Mark Wade; Kiran Meekings; Martin J Allday
Journal:  J Virol       Date:  2006-10-11       Impact factor: 5.103

3.  Epstein-Barr virus nuclear antigen 2 (EBNA2) gene deletion is consistently linked with EBNA3A, -3B, and -3C expression in Burkitt's lymphoma cells and with increased resistance to apoptosis.

Authors:  Gemma L Kelly; Anne E Milner; Rosemary J Tierney; Debbie S G Croom-Carter; Markus Altmann; Wolfgang Hammerschmidt; Andrew I Bell; Alan B Rickinson
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

4.  Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells.

Authors:  Gemma L Kelly; Anne E Milner; Gouri S Baldwin; Andrew I Bell; Alan B Rickinson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-25       Impact factor: 11.205

5.  Epstein-Barr virus nuclear protein EBNA3C is required for cell cycle progression and growth maintenance of lymphoblastoid cells.

Authors:  Seiji Maruo; Yi Wu; Satoko Ishikawa; Teru Kanda; Dai Iwakiri; Kenzo Takada
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-11       Impact factor: 11.205

6.  Truncated form of the Epstein-Barr virus protein EBNA-LP protects against caspase-dependent apoptosis by inhibiting protein phosphatase 2A.

Authors:  Julie Garibal; Emilie Hollville; Andrew I Bell; Gemma L Kelly; Benjamin Renouf; Yasushi Kawaguchi; Alan B Rickinson; Joëlle Wiels
Journal:  J Virol       Date:  2007-05-09       Impact factor: 5.103

7.  Epstein-Barr virus (EBV)-encoded RNA 2 (EBER2) but not EBER1 plays a critical role in EBV-induced B-cell growth transformation.

Authors:  Yi Wu; Seiji Maruo; Misako Yajima; Teru Kanda; Kenzo Takada
Journal:  J Virol       Date:  2007-08-08       Impact factor: 5.103

8.  Quantitative evaluation of the role of Epstein-Barr virus immediate-early protein BZLF1 in B-cell transformation.

Authors:  Koichi Ricardo Katsumura; Seiji Maruo; Yi Wu; Teru Kanda; Kenzo Takada
Journal:  J Gen Virol       Date:  2009-06-24       Impact factor: 3.891

9.  An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in burkitt lymphomagenesis: the Wp/BHRF1 link.

Authors:  Gemma L Kelly; Heather M Long; Julianna Stylianou; Wendy A Thomas; Alison Leese; Andrew I Bell; Georg W Bornkamm; Josef Mautner; Alan B Rickinson; Martin Rowe
Journal:  PLoS Pathog       Date:  2009-03-13       Impact factor: 6.823

10.  Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt's lymphoma.

Authors:  E Anderton; J Yee; P Smith; T Crook; R E White; M J Allday
Journal:  Oncogene       Date:  2007-07-23       Impact factor: 9.867

View more
  13 in total

1.  cis-Acting effects on RNA processing and Drosha cleavage prevent Epstein-Barr virus latency III BHRF1 expression.

Authors:  Li Xing; Elliott Kieff
Journal:  J Virol       Date:  2011-06-22       Impact factor: 5.103

2.  Locating Herpesvirus Bcl-2 Homologs in the Specificity Landscape of Anti-Apoptotic Bcl-2 Proteins.

Authors:  Glenna Wink Foight; Amy E Keating
Journal:  J Mol Biol       Date:  2015-05-23       Impact factor: 5.469

3.  Epstein-Barr virus (EBV) provides survival factors to EBV+ diffuse large B-cell lymphoma (DLBCL) lines and modulates cytokine induced specific chemotaxis in EBV+  DLBCL.

Authors:  Liang Wu; Barbro Ehlin-Henriksson; Xiaoying Zhou; Hong Zhu; Ingemar Ernberg; Lorand L Kis; George Klein
Journal:  Immunology       Date:  2017-08-11       Impact factor: 7.397

Review 4.  Epstein-Barr virus: more than 50 years old and still providing surprises.

Authors:  Lawrence S Young; Lee Fah Yap; Paul G Murray
Journal:  Nat Rev Cancer       Date:  2016-09-30       Impact factor: 60.716

5.  Epstein-Barr virus nuclear antigen 3A promotes cellular proliferation by repression of the cyclin-dependent kinase inhibitor p21WAF1/CIP1.

Authors:  Melissa L Tursiella; Emily R Bowman; Keith C Wanzeck; Robert E Throm; Jason Liao; Junjia Zhu; Clare E Sample
Journal:  PLoS Pathog       Date:  2014-10-02       Impact factor: 6.823

Review 6.  EBV and Apoptosis: The Viral Master Regulator of Cell Fate?

Authors:  Leah Fitzsimmons; Gemma L Kelly
Journal:  Viruses       Date:  2017-11-13       Impact factor: 5.048

7.  New Interactors of the Truncated EBNA-LP Protein Identified by Mass Spectrometry in P3HR1 Burkitt's Lymphoma Cells.

Authors:  Sonia Chelouah; Emilie Cochet; Sophie Couvé; Sandy Balkaran; Aude Robert; Evelyne May; Vasily Ogryzko; Joëlle Wiels
Journal:  Cancers (Basel)       Date:  2018-01-05       Impact factor: 6.639

8.  Burkitt lymphoma-associated network construction and important network motif analysis.

Authors:  Kunhao Wang; Chao Ma; Chong Xing; Chin-Ling Chen; Zhigang Chen; Yuxia Yao; Jianan Wang; Chunyu Tao
Journal:  Oncol Lett       Date:  2018-06-21       Impact factor: 2.967

9.  EBNA2-deleted Epstein-Barr virus (EBV) isolate, P3HR1, causes Hodgkin-like lymphomas and diffuse large B cell lymphomas with type II and Wp-restricted latency types in humanized mice.

Authors:  Chunrong Li; James C Romero-Masters; Shane Huebner; Makoto Ohashi; Mitchell Hayes; Jillian A Bristol; Scott E Nelson; Mark R Eichelberg; Nicholas Van Sciver; Erik A Ranheim; Rona S Scott; Eric C Johannsen; Shannon C Kenney
Journal:  PLoS Pathog       Date:  2020-06-15       Impact factor: 6.823

10.  A computationally designed inhibitor of an Epstein-Barr viral Bcl-2 protein induces apoptosis in infected cells.

Authors:  Erik Procko; Geoffrey Y Berguig; Betty W Shen; Yifan Song; Shani Frayo; Anthony J Convertine; Daciana Margineantu; Garrett Booth; Bruno E Correia; Yuanhua Cheng; William R Schief; David M Hockenbery; Oliver W Press; Barry L Stoddard; Patrick S Stayton; David Baker
Journal:  Cell       Date:  2014-06-19       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.